Logo

Transgenomic Said Q4 Revenue Fell 4-Percent as Losses, R&D Spending Shrank

Apr 01, 2005

NEW YORK, April 1 (GenomeWeb News) - Transgenomic yesterday reported that fourth-quarter revenue fell 4 percent as R&D spending declined and net losses narrowed.

 

Total receipts for the three months ended Dec. 31, 2004, decreased to $8 million from $8.3 million year over year.

 

R&D spending, meantime, fell to $1.3 million from $2.2 million year over year.

 

This decrease helped net losses to decline to $6.9 million, or $.24 per share, from $8.6 million, or $.32 per share, during the same quarter last year.

 

Transgenomic said it had around $1 million in cash, equivalents, and short-term investments as of Dec. 31, 2004.

 

As GenomeWeb News reported, Transgenomic will likely receive a delisting warning from the Nasdaq exchange because its shares have closed below $1 for 30 consecutive trading days.

 

In February, the company wrapped up a reorganization announced in November.

Breaking News
The Scan

Lung Cancer Response to Checkpoint Inhibitors Reflected in Circulating Tumor DNA

In non-small cell lung cancer patients, researchers find in JCO Precision Oncology that survival benefits after immune checkpoint blockade coincide with a dip in ctDNA levels.

Study Reviews Family, Provider Responses to Rapid Whole-Genome Sequencing Follow-up

Investigators identified in the European Journal of Human Genetics variable follow-up practices after rapid whole-genome sequencing.

BMI-Related Variants Show Age-Related Stability in UK Biobank Participants

Researchers followed body mass index variant stability with genomic structural equation modeling and genome-wide association studies of 40- to 72-year olds in PLOS Genetics.

Genome Sequences Reveal Range Mutations in Induced Pluripotent Stem Cells

Researchers in Nature Genetics detect somatic mutation variation across iPSCs generated from blood or skin fibroblast cell sources, along with selection for BCOR gene mutations.